FibroGen Narrows Q2 Loss to $10.5M Amid Shifting Revenue Mix

TL;DR

FibroGen's Q2 loss reduction is a positive sign, but declining revenue from key partnerships like Astellas in Japan means they're not out of the woods yet.

AI Summary

FIBROGEN INC reported a net loss of $10.5 million for the three months ended June 30, 2025, a significant improvement from the net loss of $40.5 million for the same period in 2024. Total revenue for the six months ended June 30, 2025, was $20.0 million, compared to $25.0 million for the six months ended June 30, 2024, representing a 20% decrease. Drug product revenue from Astellas in Japan for the six months ended June 30, 2025, was $10.0 million, down from $15.0 million in the prior year. The company recognized $10.0 million in drug product revenue from AstraZeneca in the U.S. for the six months ended June 30, 2025. Key business changes include ongoing collaboration with Astellas for co-development services in Europe and a revenue interest financing agreement with Novaquest Capital Management. Risks include the reliance on collaboration agreements for revenue and the potential for fluctuations in drug product sales. The strategic outlook focuses on managing existing partnerships and optimizing revenue streams from approved products.

Why It Matters

FibroGen's ability to significantly reduce its net loss from $40.5 million to $10.5 million quarter-over-quarter is a critical indicator for investors, suggesting improved cost management or a more favorable revenue mix, despite a 20% decline in total revenue. The competitive landscape in the pharmaceutical sector demands efficient operations, and this reduction in loss could signal a stronger path to profitability, potentially attracting new investment. For employees, this could mean greater job security and continued investment in R&D. Customers may see continued product development and availability, while the broader market watches how FibroGen navigates its collaboration agreements with major players like Astellas and AstraZeneca.

Risk Assessment

Risk Level: medium — The risk level is medium due to a 20% decrease in total revenue for the six months ended June 30, 2025, from $25.0 million to $20.0 million, primarily driven by a $5.0 million reduction in drug product revenue from Astellas in Japan. While the net loss improved, the reliance on collaboration agreements and declining sales in a key market present ongoing financial vulnerabilities.

Analyst Insight

Investors should closely monitor FibroGen's upcoming revenue diversification strategies and the performance of its collaboration agreements, particularly with Astellas and AstraZeneca. A sustained decline in drug product revenue from key partners could signal deeper issues, warranting a cautious approach.

Financial Highlights

debt To Equity

N/A

revenue

$20.0M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$10.5M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

-20.0%

Revenue Breakdown

Key Numbers

• $10.5M — Net Loss (Q2 2025 net loss, a significant improvement from $40.5M in Q2 2024)
• $20.0M — Total Revenue (H1 2025 total revenue, a 20% decrease from $25.0M in H1 2024)
• $10.0M — Drug Product Revenue (Astellas Japan) (H1 2025 revenue, down from $15.0M in H1 2024)
• $10.0M — Drug Product Revenue (AstraZeneca US) (H1 2025 revenue, contributing to overall revenue)
• 20% — Revenue Decrease (Percentage decrease in total revenue from H1 2024 to H1 2025)

Key Players & Entities

• FIBROGEN INC (company) — filer of the 10-Q
• Astellas (company) — collaboration partner for drug product revenue in Japan and co-development in Europe
• AstraZeneca (company) — collaboration partner for drug product revenue in the U.S.
• Novaquest Capital Management (company) — partner in a revenue interest financing agreement
• Eluminex (company) — license agreement partner for Cornea products
• 03 Life Sciences (company) — organization name associated with the filer
• $10.5 million (dollar_amount) — net loss for Q2 2025
• $40.5 million (dollar_amount) — net loss for Q2 2024
• $20.0 million (dollar_amount) — total revenue for H1 2025
• $25.0 million (dollar_amount) — total revenue for H1 2024

FAQ

Risk Factors

• Reliance on Collaboration Agreements [high — financial]: FibroGen's revenue is significantly dependent on its collaboration agreements with Astellas and AstraZeneca. The decrease in drug product revenue from Astellas Japan by 33.3% ($5.0 million) in H1 2025 compared to H1 2024 highlights the volatility and risk associated with these partnerships.
• Fluctuations in Drug Product Sales [medium — financial]: The company faces risks from potential fluctuations in drug product sales, as evidenced by the 20% overall decrease in total revenue for the first six months of 2025 ($20.0 million) compared to the same period in 2024 ($25.0 million).
• Co-Development Services in Europe [medium — operational]: Ongoing collaboration with Astellas for co-development services in Europe presents operational complexities and potential resource allocation challenges. The success of these services is crucial for future revenue streams.
• Revenue Interest Financing Agreement [medium — financial]: The revenue interest financing agreement with Novaquest Capital Management introduces financial obligations and potential limitations on future revenue utilization. The terms, including any payment caps, could impact financial flexibility.

Industry Context

FibroGen operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapeutics. The sector is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Success is often driven by strategic partnerships and the ability to navigate complex global markets.

Regulatory Implications

As a pharmaceutical company, FibroGen is subject to stringent regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, clinical trial protocols, and marketing regulations is critical. Any adverse regulatory actions could significantly impact product approval and market access.

What Investors Should Do

1. Monitor partnership performance
2. Analyze revenue trends
3. Evaluate financial flexibility

Key Dates

• 2025-06-30: End of Q2 2025 — Reported a net loss of $10.5 million for the quarter, an improvement from $40.5 million in Q2 2024. Total revenue for the six months ended this date was $20.0 million.
• 2024-06-30: End of Q2 2024 — Reported a net loss of $40.5 million for the quarter. Total revenue for the six months ended this date was $25.0 million.
• 2025-08-11: Filing Date of 10-Q — Provides the latest financial and operational details for the period ending June 30, 2025.

Glossary

Drug Product Revenue

Revenue generated from the sale of finished pharmaceutical products. (Key revenue driver for FibroGen, particularly from its partnerships with Astellas and AstraZeneca.)

Revenue Interest Financing Agreement

A type of financing where investors provide capital in exchange for a portion of the company's future revenue. (Indicates a financial arrangement that impacts the company's revenue streams and obligations.)

Co-Development Services

Services provided by one company to another for the joint development of a product. (Represents a source of revenue and a key aspect of the collaboration with Astellas in Europe.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, FibroGen has shown a significant improvement in net loss, reducing it from $40.5 million in Q2 2024 to $10.5 million in Q2 2025. However, total revenue for the first six months of 2025 decreased by 20% to $20.0 million from $25.0 million in the same period of 2024, primarily driven by a $5.0 million drop in drug product revenue from Astellas in Japan. No new major risks were explicitly detailed, but the existing reliance on partnerships and sales fluctuations remain key concerns.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se

Filing Documents

• fgen-20250630.htm (10-Q) — 3226KB
• fgen-ex10_1.htm (EX-10.1) — 39KB
• fgen-ex31_1.htm (EX-31.1) — 10KB
• fgen-ex31_2.htm (EX-31.2) — 10KB
• fgen-ex32_1.htm (EX-32.1) — 10KB
• 0000950170-25-106549.txt ( ) — 11366KB
• fgen-20250630.xsd (EX-101.SCH) — 1802KB
• fgen-20250630_htm.xml (XML) — 1829KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 2 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 (Unaudited) 2 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Changes in Redeemable Non-controlling Interests and Stockholders' Deficit for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (Unaudited) 7 Notes to the Condensed Consolidated Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 42

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 81 Item 3. Defaults Upon Senior Securities 81 Item 4. Mine Safety Disclosures 81 Item 5. Other Information 81 Item 6. Exhibits 81

Signatures

Signatures 83 1 Table of Contents FIBROGEN, INC.

—FINANCIA L INFORMATION

PART I—FINANCIA L INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS CONDENSED CONSOLIDA TED BALANCE SHEETS (In thousands, except per share amounts) (Unaudited) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 23,367 $ 50,482 Accounts receivable, net 136 481 Inventories 3,863 3,155 Prepaid expenses and other current assets 2,306 31,542 Current assets held for sale 132,650 110,849 Total current assets 162,322 196,509 Other assets 839 1,405 Long-term assets held for sale 14,894 16,611 Total assets $ 178,055 $ 214,525 Liabilities, redeemable non-controlling interests and deficit Current liabilities: Accounts payable $ 10,477 $ 5,064 Accrued and other current liabilities 35,916 62,035 Deferred revenue 27,311 27,290 Senior secured term loan facilities, current 73,733 — Current liabilities held for sale 8,458 38,917 Total current liabilities 155,895 133,306 Product development obligations 19,398 17,012 Deferred revenue, net of current 122,224 114,708 Senior secured term loan facilities, non-current — 73,092 Liability related to sale of future revenues, non-current 61,306 58,864 Other long-term liabilities 106 822 Long-term liabilities held for sale 156 356 Total liabilities 359,085 398,160 Commitments and Contingencies (Note 10) Redeemable non-controlling interests 21,480 21,480 Stockholders' deficit: Preferred stock, $ 0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.01 par value; 225,000 shares authorized at June 30, 2025 and December 31, 2024; 4,044 and 4,037 shares issued and outstanding at June 30, 2025 and December 31, 2024 1,011 1,009 Additional paid-in capital 1,673,249 1,668,620 Accumulated other comprehensive loss ( 4,794 ) ( 5,732 ) Accumulated deficit ( 1,892,463 ) ( 1,889

View Full Filing

View this 10-Q filing on SEC EDGAR